Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: An Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 827-833

  Cianfrocca, Mary ^a   Lee, Sandra ^b   Von Roenn, Jamie ^a   Rudek, Michelle A ^c   Dezube, Bruce J ^d   Krown, Susan E ^e   Sparano, Joseph A ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

AIDS; HIV infection; Kaposi's sarcoma; Paclitaxel; Protease inhibitors

Indexed keywords

CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; INDINAVIR; NELFINAVIR; PACLITAXEL; PROTEINASE INHIBITOR; ZIDOVUDINE;

ABDOMINAL CRAMP; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG TOXICITY; EYE IRRITATION; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILEUS; INFECTION; KAPOSI SARCOMA; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS; SARCOMA, KAPOSI;

EID: 80054740151     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1509-4     Document Type: Article

References (39)

1. RJ Biggar PS Rosenberg T Cote 1996 Kaposi's sarcoma, non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/cancer match study group Int J Cancer 68 754 758 8980179 10.1002/(SICI)1097-0215(19961211)68: 6<754::AID-IJC11>3.0.CO;2-0 1:STN:280:DyaK2s7jsVKiuw%3D%3D (Pubitemid 27062036)
2. PS Moore Y Chang 1995 Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection N Engl J Med 332 1181 1185 7700310 10.1056/NEJM199505043321801 1:CAS:528:DyaK2MXlvFCqsbc%3D
3. Y Chang E Cesarman MS Pessin, et al. 1994 Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma Science 266 1865 1869 7997879 10.1126/science.7997879 1:CAS:528:DyaK2MXislCjs78%3D
4. R Masood J Cai T Zheng DL Smith Y Naidu PS Gill 1997 Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma Proc Natl Acad Sci USA 94 979 984 9023368 10.1073/pnas.94.3.979 1:CAS:528:DyaK2sXhtVOqtbY%3D (Pubitemid 27074433)
5. S Montaner 2007 Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma Cell Cycle 6 438 443 17329974 10.4161/cc.6.4.3843 1:CAS:528:DC%2BD2sXnvFCltrg%3D (Pubitemid 46393447)
6. Y Zeng X Zhang Z Huang, et al. 2007 Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling J Virol 81 2401 2417 17151125 10.1128/JVI.02024-06 1:CAS:528:DC%2BD2sXitVOgs7k%3D
7. Y Aoki G Tosato 2004 HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity Blood 104 810 814 15073028 10.1182/blood-2003-07- 2533 1:CAS:528:DC%2BD2cXmtlCkur8%3D (Pubitemid 38970578)
8. MC Deregibus V Cantaluppi S Doublier, et al. 2002 HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells J Biol Chem 277 25195 25202 11994280 10.1074/jbc. M200921200 1:CAS:528:DC%2BD38XlsVWiurs%3D (Pubitemid 34951826)
9. DD Ho 1995 Time to hit HIV, early and hard N Engl J Med 333 450 451 7616996 10.1056/NEJM199508173330710 1:STN:280:DyaK2Mzkt1Wquw%3D%3D
10. FJ Palella Jr KM Delaney AC Moorman, et al. 1998 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators N Engl J Med 338 853 860 9516219 10.1056/NEJM199803263381301 (Pubitemid 28135961)
11. LP Jacobson TE Yamashita R Detels, et al. 1999 Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS cohort study J Acquir Immune Defic Syndr 21 Suppl 1 S34 S41 10430217 1:CAS:528: DC%2BD3cXjtlKktb0%3D (Pubitemid 29357647)
12. C Flexner 1998 HIV-protease inhibitors N Engl J Med 338 1281 1292 9562584 10.1056/NEJM199804303381808 1:CAS:528:DyaK1cXivF2qt78%3D (Pubitemid 28216584)
13. A Mastrolorenzo S Rusconi A Scozzafava G Barbaro CT Supuran 2007 Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors Curr Med Chem 14 2734 2748 18045120 10.2174/092986707782360141 1:CAS:528:DC%2BD1cXhtlSkurc%3D (Pubitemid 350130917)
14. V Dixit N Hariparsad F Li P Desai KE Thummel JD Unadkat 2007 Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions Drug Metab Dispos 35 1853 1859 17639026 10.1124/dmd.107.016089 1:CAS:528:DC%2BD2sXhtFansbbL (Pubitemid 47481578)
15. A Jackson S Taylor M Boffito 2004 Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors AIDS Rev 6 208 217 15700619 (Pubitemid 40227882)
16. LI Malaty JJ Kuper 1999 Drug interactions of HIV protease inhibitors Drug Saf 20 147 169 10082072 10.2165/00002018-199920020-00005 1:CAS:528: DyaK1MXhvVGnsrg%3D (Pubitemid 29101279)
17. A Tulpule J Groopman MW Saville, et al. 2002 Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma Cancer 95 147 154 12115328 10.1002/cncr.10634 1:CAS:528:DC%2BD38XlslyqsLc%3D (Pubitemid 34743493)
18. PS Gill A Tulpule BM Espina, et al. 1999 Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma J Clin Oncol 17 1876 1883 10561228 1:CAS:528:DyaK1MXktV2qtbg%3D (Pubitemid 29269260)
19. L Welles MW Saville J Lietzau, et al. 1998 Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma J Clin Oncol 16 1112 1121 9508198 1:CAS:528:DyaK1cXitVKitrc%3D (Pubitemid 28108748)
20. MW Saville J Lietzau JM Pluda, et al. 1995 Treatment of HIV-associated Kaposi's sarcoma with paclitaxel Lancet 346 26 28 7603142 10.1016/S0140-6736(95) 92654-2 1:STN:280:DyaK2Mzis1OgsQ%3D%3D
21. JW Harris A Rahman BR Kim FP Guengerich JM Collins 1994 Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme Cancer Res 54 4026 4035 7913410 1:CAS:528:DyaK2cXlt1Cmsbc%3D (Pubitemid 24258105)
22. A Sparreboom J van Asperen U Mayer, et al. 1997 Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc Natl Acad Sci USA 94 2031 2035 9050899 10.1073/pnas.94.5.2031 1:CAS:528:DyaK2sXhslCjs7o%3D (Pubitemid 27113956)
23. DS Sonnichsen MV Relling 1994 Clinical pharmacokinetics of paclitaxel Clin Pharmacokinet 27 256 269 7834963 10.2165/00003088-199427040-00002 1:CAS:528:DyaK2MXitFSru7Y%3D (Pubitemid 24315086)
24. DS Sonnichsen CA Hurwitz CB Pratt JJ Shuster MV Relling 1994 Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors J Clin Oncol 12 532 538 7907130 1:STN:280:DyaK2c7msFKrtQ%3D%3D (Pubitemid 24079895)
25. S Mielke A Sparreboom SM Steinberg, et al. 2005 Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer Clin Cancer Res 11 4843 4850 16000582 10.1158/1078-0432.CCR-05- 0298 1:CAS:528:DC%2BD2MXlvVGgs7w%3D (Pubitemid 41557204)
26. L Gianni CM Kearns A Giani, et al. 1995 Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13 180 190 7799018 1:STN:280:DyaK2M%2Fps12ntg%3D%3D
27. S Mielke A Sparreboom D Behringer K Mross 2005 Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen Anticancer Res 25 4423 4427 16334120 1:CAS:528:DC%2BD2MXhtlWgt7fE (Pubitemid 41729490)
28. MT Huizing G Giaccone LJ van Warmerdam, et al. 1997 Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European cancer centre J Clin Oncol 15 317 329 8996159 1:CAS:528:DyaK2sXnsV2lsg%3D%3D (Pubitemid 27020590)
29. A Sparreboom J Verweij 2003 Paclitaxel pharmacokinetics, threshold models, and dosing strategies J Clin Oncol 21 2803 2804 12860961 10.1200/JCO.2003.99.038 author reply 2805-6
30. VR Nannan Panday RM Hoetelmans RP van Heeswijk, et al. 1999 Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma-drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study Cancer Chemother Pharmacol 43 516 519 10321513 10.1007/s002800050932 1:STN:280:DyaK1M3ltlCgsg%3D%3D (Pubitemid 29187592)
31. Duchin K, Sun J, Tan M, Ilaw M, Cabriales S, Espina BM, East D, Tulpule A, Gill PS 1997 Pharmacokinetics of low-dose Paxene (paclitaxel) in patients with refractory or relapsed AIDS-related Kaposi's sarcoma. Proc Am Soc Clin. 15 Abstract 235
32. M Cianfrocca TP Cooley JY Lee, et al. 2002 Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study J Clin Oncol 20 153 159 11773164 10.1200/JCO.20.1.153 1:CAS:528:DC%2BD38XnsFertw%3D%3D (Pubitemid 34032606)
33. A Sparreboom P de Bruijn K Nooter WJ Loos G Stoter J Verweij 1998 Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection J Chromatogr B Biomed Sci Appl 705 159 164 9498685 10.1016/S0378-4347(97)00502-1 1:CAS:528:DyaK1cXlsFaktQ%3D%3D (Pubitemid 28045670)
34. SE Krown C Metroka JC Wernz 1989 Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS clinical trials group oncology committee J Clin Oncol 7 1201 1207 2671281 1:STN:280:DyaL1MzmtFGmsQ%3D%3D (Pubitemid 19220121)
35. L Pantanowitz HP Schlecht BJ Dezube 2006 The growing problem of non-AIDS-defining malignancies in HIV Curr Opin Oncol 18 469 478 16894295 10.1097/01.cco.0000239886.13537.ed (Pubitemid 44199843)
36. L Martin-Carbonero A Barrios P Saballs, et al. 2004 Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma Aids 18 1737 1740 15280789 10.1097/01.aids.0000131385.60974.b9 1:CAS:528:DC%2BD2cXlvF2ksL0%3D (Pubitemid 39095795)
37. L Fumagalli M Zucchetti I Parisi, et al. 2000 The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma Cancer Chemother Pharmacol 45 495 501 10854138 10.1007/s002800051025 1:CAS:528:DC%2BD3cXislejsr4%3D (Pubitemid 30316911)
38. BS Kappelhoff AD Huitema AT Mairuhu JH Schellens JH Beijnen 2005 No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel Anticancer Drugs 16 627 630 15930890 10.1097/00001813-200507000-00006 1:CAS:528:DC%2BD2MXks1Glu74%3D (Pubitemid 40863095)
39. L Ratner J Lee S Tang, et al. 2001 Chemotherapy for human immunodeficiency virus-associated non-hodgkin's lymphoma in combination with highly active antiretroviral therapy J Clin Oncol 19 2171 2178 11304769 1:CAS:528:DC%2BD3MXjsFeru7o%3D (Pubitemid 32366971)